Christophe Weber, Takeda CEO (Kosuke Okahara/Bloomberg via Getty Images)
July 31, 2024 01:21 PM EDT
R&D
Pharma

Take­da de­fends Alzheimer's pact, TYK2 po­ten­tial as re­struc­tur­ing is in 'full swing'

Kyle LaHucik

Senior Reporter

In its quar­ter­ly up­date on Wednes­day, Take­da ex­ec­u­tives said the Japan-based phar­ma gi­ant’s $900 mil­lion re­struc­tur­ing is in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times